{"disease":{"id":"antineoplastic-agents","name":"antineoplastic agents"},"drugs":{"marketed":[],"pipeline":[],"offLabel":[],"totalMarketed":0,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT06535568","title":"Single vs. Dual Antiplatelet Therapy in Elderly or HBR Patients Undergoing Percutaneous Intervention With DCB (PICCOLETO IV-EPIC 38)","phase":"NA","overall_status":"RECRUITING","enrollment_count":576,"lead_sponsor_name":"Fondazione Ricerca e Innovazione Cardiovascolare ETS","has_results":false},{"nct_id":"NCT03606369","title":"Effectiveness and Quality of Life Analysis of Palonosetron Against Ondansetron Combined With Dexamethasone and Fosaprepitant in Prevention of Acute and Delayed Emesis Associated to Chemotherapy Moderate and Highly Emetogenic in Breast Cancer.","phase":"PHASE2, PHASE3","overall_status":"UNKNOWN","enrollment_count":560,"lead_sponsor_name":"Instituto Nacional de Cancerologia de Mexico","has_results":false},{"nct_id":"NCT03711110","title":"Cardiovascular Prevention Strategies in Elderly Patients With Cancer (CARTIER Clinical Trial)","phase":"NA","overall_status":"RECRUITING","enrollment_count":514,"lead_sponsor_name":"Fundación Instituto de Estudios de Ciencias de la Salud de Castilla y León","has_results":false},{"nct_id":"NCT03284255","title":"Bioheart Rapamycin Drug-Eluting Bioresorbable Coronary Stent System Clinical Study","phase":"NA","overall_status":"UNKNOWN","enrollment_count":431,"lead_sponsor_name":"Shanghai Bio-heart Biological Technology Co., Ltd.","has_results":false},{"nct_id":"NCT07124858","title":"Prospective National Cohort Evaluating Prognostic Factors for Efficacy of Fruquintinib Treatment in Patients With Metastatic Colorectal Cancer","phase":"NA","overall_status":"NOT_YET_RECRUITING","enrollment_count":300,"lead_sponsor_name":"Federation Francophone de Cancerologie Digestive","has_results":false},{"nct_id":"NCT04862780","title":"(SYMPHONY) Phase 1/2 Study Targeting EGFR Resistance Mechanisms in NSCLC","phase":"PHASE1","overall_status":"TERMINATED","enrollment_count":177,"lead_sponsor_name":"Blueprint Medicines Corporation","has_results":false},{"nct_id":"NCT04613765","title":"A Mixed Method to Study Adherence to Oral Anticancer Medications in a Multilingual and Multicultural Setting","phase":"","overall_status":"UNKNOWN","enrollment_count":113,"lead_sponsor_name":"Jules Bordet Institute","has_results":false},{"nct_id":"NCT05241873","title":"(Concerto) Study of BLU-451 in Advanced Cancers With EGFR Exon 20 Insertion Mutations","phase":"PHASE1","overall_status":"TERMINATED","enrollment_count":103,"lead_sponsor_name":"Blueprint Medicines Corporation","has_results":false},{"nct_id":"NCT07319364","title":"A Real-World Study of Fecal Transplants for Cancer Therapy Side Effects","phase":"PHASE1","overall_status":"RECRUITING","enrollment_count":90,"lead_sponsor_name":"Second Affiliated Hospital, School of Medicine, Zhejiang University","has_results":false},{"nct_id":"NCT06886659","title":"A Study to Compare PK, Immunogenicity and Safety of Trastuzumab of Incepta Pharmaceuticals Ltd With Trastuzumab (Roche)","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":80,"lead_sponsor_name":"Incepta Pharmaceuticals Ltd","has_results":false},{"nct_id":"NCT04566952","title":"Anlotinib Combined With Dose-reduced Olaparib in Patients With Platinum-Sensitive Recurrent Ovarian Cancer","phase":"PHASE2","overall_status":"UNKNOWN","enrollment_count":68,"lead_sponsor_name":"Xiaoxiang Chen","has_results":false},{"nct_id":"NCT06755684","title":"Neoadjuvant Befotertinib Combined Bevacizumab or Platinum-based Double Chemotherapy for Resectable Locally-advanced EGFR Mutation-positive Non-Small Cell Lung Cancer","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":60,"lead_sponsor_name":"Peng Zhang","has_results":false},{"nct_id":"NCT04807166","title":"Anlotinib Combined With Carboplatin/Paclitaxel as First-line Treatment in Patients With Advanced Ovarian Cancer","phase":"PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":56,"lead_sponsor_name":"Wenjun Cheng","has_results":false},{"nct_id":"NCT05030077","title":"Anlotinib Combined With Platinum/Gemcitabine for First Line Treatment of Advanced Urothelial Carcinoma","phase":"PHASE2","overall_status":"UNKNOWN","enrollment_count":53,"lead_sponsor_name":"Tianjin Medical University Second Hospital","has_results":false},{"nct_id":"NCT04572451","title":"Safety of SBRT With Anti-PD1 and Anti-IL-8 for the Treatment of Multiple Metastases in Advanced Solid Tumors and Melanoma","phase":"PHASE1","overall_status":"RECRUITING","enrollment_count":50,"lead_sponsor_name":"Yana Najjar","has_results":false},{"nct_id":"NCT06676527","title":"Vorolanib in the Second-line Treatment of Patients With Unresectable or Metastatic Renal Cell Carcinoma","phase":"","overall_status":"RECRUITING","enrollment_count":39,"lead_sponsor_name":"Jinling Hospital, China","has_results":false},{"nct_id":"NCT04556071","title":"Efficacy and Safety of Niraparib Combined With Bevacizumab in Platinum Refractory/Resistant Recurrent Ovarian Cancer","phase":"PHASE2","overall_status":"UNKNOWN","enrollment_count":32,"lead_sponsor_name":"Xiaoxiang Chen","has_results":false},{"nct_id":"NCT04309084","title":"Natural Killer Cell (CYNK-001) Infusions in Adults With Multiple Myeloma","phase":"PHASE1","overall_status":"UNKNOWN","enrollment_count":29,"lead_sponsor_name":"Celularity Incorporated","has_results":false},{"nct_id":"NCT04310592","title":"Natural Killer Cell (CYNK-001) Infusions in Adults with AML","phase":"PHASE1","overall_status":"TERMINATED","enrollment_count":27,"lead_sponsor_name":"Celularity Incorporated","has_results":false},{"nct_id":"NCT04518852","title":"TACE, Sorafenib and PD-1 Monoclonal Antibody in the Treatment of HCC","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":27,"lead_sponsor_name":"Sichuan Cancer Hospital and Research Institute","has_results":false},{"nct_id":"NCT04002284","title":"Anlotinib in Metastatic HER2 Negative Breast Cancer","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":26,"lead_sponsor_name":"Peng Yuan","has_results":false},{"nct_id":"NCT05964101","title":"Nivolumab Combined With Chemotherapy in the Treatment of Primary Tracheal Squamous Cell Carcinoma","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":25,"lead_sponsor_name":"The First Affiliated Hospital of Guangzhou Medical University","has_results":false},{"nct_id":"NCT05153408","title":"(HARMONY) Study of BLU-701 in EGFR-mutant NSCLC","phase":"PHASE1","overall_status":"TERMINATED","enrollment_count":20,"lead_sponsor_name":"Blueprint Medicines Corporation","has_results":false},{"nct_id":"NCT03403777","title":"Avelumab in Refractory Testicular Germ Cell Cancer.","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":8,"lead_sponsor_name":"National Cancer Institute, Slovakia","has_results":false}],"total":24},"guidelines":[],"source":"Drug Landscape verified database"}